| 前收市價 | 29.70 |
| 開市 | 29.84 |
| 買盤 | 29.90 x 200 |
| 賣出價 | 30.08 x 200 |
| 今日波幅 | 29.64 - 30.05 |
| 52 週波幅 | 17.53 - 45.58 |
| 成交量 | |
| 平均成交量 | 1,144,204 |
| 市值 | 4.354B |
| Beta 值 (5 年，每月) | 0.75 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -1.81 |
| 業績公佈日 | 2024年5月13日 - 2024年5月27日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 50.86 |
ZacksZacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand have been highlighted in this Industry Outlook article.
Zacks5 Biotech Stocks Worth Adding to Your Portfolio in 2024
New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position BMRN, BPMC, IMVT, KYMR and LGND well amid volatility.
Insider MonkeyShould You Hold Immunovant (IMVT)?
Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarter 2024 investor letter. A copy of the same can be downloaded here. The fund advanced 8.92% (Institutional Shares) in the quarter compared to an 8.52% gain for the Russell 3000 Health Care Index (benchmark) and a 10.56% increase for the S&P […]
